{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:48Z","timestamp":1784020008782,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07992-8","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:25:18Z","timestamp":1780586718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2172-1058","authenticated-orcid":false,"given":"Imad","family":"Barjij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9164-2046","authenticated-orcid":false,"given":"Sarah","family":"Naciri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihame","family":"Lkhoyaali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoussane","family":"Kharmoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"Inrhaouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Elghissassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Boutayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-6707","authenticated-orcid":false,"given":"Hind","family":"Mrabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"7992_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14215467","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Jacobs F, Debien V et al (2022) Post-neoadjuvant treatment strategies for patients with early breast cancer. Cancers Published online. https:\/\/doi.org\/10.3390\/CANCERS14215467","journal-title":"Cancers Published online"},{"key":"7992_CR2","doi-asserted-by":"publisher","first-page":"175883592211396","DOI":"10.1177\/17588359221139601","volume":"14","author":"N Ciriaco","year":"2022","unstructured":"Ciriaco N, Zamora E, Escriv\u00e1-de-Roman\u00ed S et al (2022) Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response. Therapeutic Adv Med Oncol 14:17588359221139601. https:\/\/doi.org\/10.1177\/17588359221139601","journal-title":"Therapeutic Adv Med Oncol"},{"key":"7992_CR3","doi-asserted-by":"publisher","unstructured":"Wang R, Wang B, Zhang H et al (2024) Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy. Breast (Edinburgh, Scotland). Published online 2024. https:\/\/doi.org\/10.1016\/J.BREAST.2024.103738","DOI":"10.1016\/J.BREAST.2024.103738"},{"key":"7992_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/S12010-022-03946-0","author":"B Wei","year":"2022","unstructured":"Wei B, Shan Y, Du Z et al (2022) Identifying circulating tumor DNA mutations associated with neoadjuvant chemotherapy efficacy in local advanced breast cancer. Appl Biochem Biotechnol Published online. https:\/\/doi.org\/10.1007\/S12010-022-03946-0","journal-title":"Appl Biochem Biotechnol Published online"},{"key":"7992_CR5","doi-asserted-by":"publisher","unstructured":"Davis AA, Cristofanilli M (2020) Minimal residual disease in patients with nonmetastatic triple-negative breast cancer: Positive, negative, or a more complex issue? JAMA Oncology. Published online 2020. https:\/\/doi.org\/10.1001\/JAMAONCOL.2020.2285","DOI":"10.1001\/JAMAONCOL.2020.2285"},{"key":"7992_CR6","doi-asserted-by":"publisher","unstructured":"Lu Y, Ren L, Yang M, Liu J (2025) Clinical management of circulating tumor DNA in breast cancer: Detection, prediction, and monitoring. Breast Cancer: Targets and Therapy. Published online 2025. https:\/\/doi.org\/10.2147\/BCTT.S542704","DOI":"10.2147\/BCTT.S542704"},{"key":"7992_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTRV.2022.102362","author":"A Papakonstantinou","year":"2022","unstructured":"Papakonstantinou A, Gonzalez NS, Pimentel I et al (2022) Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. Cancer Treat Reviews Published online. https:\/\/doi.org\/10.1016\/J.CTRV.2022.102362","journal-title":"Cancer Treat Reviews Published online"},{"issue":"1","key":"7992_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13058-025-01986-y","volume":"27","author":"D Zhang","year":"2025","unstructured":"Zhang D, Jahanfar S, Rabinowitz JB et al (2025) Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Res 27(1):38. https:\/\/doi.org\/10.1186\/s13058-025-01986-y","journal-title":"Breast Cancer Res"},{"key":"7992_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2023.04.008","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Swigart LB, Ahmed Z et al (2023) Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell Published online. https:\/\/doi.org\/10.1016\/J.CCELL.2023.04.008","journal-title":"Cancer Cell Published online"},{"key":"7992_CR10","doi-asserted-by":"publisher","unstructured":"Ortolan E, Appierto V, Silvestri M et al (2021) Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO open. Published online 2021. https:\/\/doi.org\/10.1016\/J.ESMOOP.2021.100086","DOI":"10.1016\/J.ESMOOP.2021.100086"},{"key":"7992_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-023-03163-4","author":"Z Liu","year":"2023","unstructured":"Liu Z, Yu B, Su M et al (2023) Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer. BMC Med Published online. https:\/\/doi.org\/10.1186\/S12916-023-03163-4","journal-title":"BMC Med Published online"},{"key":"7992_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-025-03725-4","author":"EA Mittendorf","year":"2025","unstructured":"Mittendorf EA, Assaf ZJ, Harbeck N et al (2025) Peri-operative atezolizumab in early-stage triple-negative breast cancer: Final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat Med Published online. https:\/\/doi.org\/10.1038\/S41591-025-03725-4","journal-title":"Nat Med Published online"},{"issue":"1","key":"7992_CR13","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","volume":"16","author":"MJM Magbanua","year":"2025","unstructured":"Magbanua MJM, Manon NA, Wolf DM et al (2025) Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun 16(1):9945. https:\/\/doi.org\/10.1038\/s41467-025-65432-5","journal-title":"Nat Commun"},{"key":"7992_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/S41523-024-00653-3","author":"F Panet","year":"2024","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M (2024) Use of ctDNA in early breast cancer: Analytical validity and clinical potential. npj Breast Cancer Published online. https:\/\/doi.org\/10.1038\/S41523-024-00653-3","journal-title":"npj Breast Cancer Published online"},{"key":"7992_CR15","doi-asserted-by":"publisher","unstructured":"Shaw J, Page K, Wren E et al (2024) Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer. JCO Precision Oncology. Published online 2024. https:\/\/doi.org\/10.1200\/PO.23.00456","DOI":"10.1200\/PO.23.00456"},{"key":"7992_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-025-13526-0","volume":"25","author":"S Niu","year":"2025","unstructured":"Niu S, Sun T, Wang M et al (2025) Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis. BMC Cancer 25:115. https:\/\/doi.org\/10.1186\/s12885-025-13526-0","journal-title":"BMC Cancer"},{"issue":"2","key":"7992_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jncc.2024.04.005","volume":"4","author":"N Guo","year":"2024","unstructured":"Guo N, Zhou Q, Zhang M et al (2024) The prognostic role of circulating tumor DNA across breast cancer molecular subtypes: A systematic review and meta-analysis. J Natl Cancer Cent 4(2):153\u2013161. https:\/\/doi.org\/10.1016\/j.jncc.2024.04.005","journal-title":"J Natl Cancer Cent"},{"key":"7992_CR18","doi-asserted-by":"publisher","first-page":"1735752","DOI":"10.3389\/fonc.2026.1735752","volume":"16","author":"H You","year":"2026","unstructured":"You H, He J, Tian T (2026) Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis. Front Oncol 16:1735752. https:\/\/doi.org\/10.3389\/fonc.2026.1735752","journal-title":"Front Oncol"},{"key":"7992_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-71236-Y","author":"L Cavallone","year":"2020","unstructured":"Cavallone L, Aguilar-Mahecha A, Lafleur J et al (2020) Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep Published online. https:\/\/doi.org\/10.1038\/S41598-020-71236-Y","journal-title":"Sci Rep Published online"},{"issue":"1","key":"7992_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41512-019-0050-0","volume":"3","author":"WJA Grooten","year":"2019","unstructured":"Grooten WJA, Tseli E, \u00c4ng BO et al (2019) Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS\u2014aspects of interrater agreement. Diagn Prognostic Res 3(1):5. https:\/\/doi.org\/10.1186\/s41512-019-0050-0","journal-title":"Diagn Prognostic Res"},{"issue":"1","key":"7992_CR21","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","volume":"170","author":"KGM Moons","year":"2019","unstructured":"Moons KGM, Wolff RF, Riley RD et al (2019) PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. Ann Intern Med 170(1):W1\u2013W33. https:\/\/doi.org\/10.7326\/M18-1377","journal-title":"Ann Intern Med"},{"key":"7992_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3145","author":"FO Ademuyiwa","year":"2025","unstructured":"Ademuyiwa FO, Cynthia X, Weilbaecher KN et al (2025) Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer. Clin Cancer Res Published online. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3145","journal-title":"Clin Cancer Res Published online"},{"key":"7992_CR23","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.jlb.2024.100168","volume":"6","author":"NL Shan","year":"2024","unstructured":"Shan NL, Gould B, Wang X et al (2024) Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. J Liquid Biopsy 6:100168. https:\/\/doi.org\/10.1016\/j.jlb.2024.100168","journal-title":"J Liquid Biopsy"},{"issue":"10","key":"7992_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","volume":"34","author":"HA Parsons","year":"2023","unstructured":"Parsons HA, Blewett T, Chu X et al (2023) Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol 34(10):899\u2013906. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.004","journal-title":"Ann Oncol"},{"key":"7992_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2025.105286","author":"MJ Elliott","year":"2025","unstructured":"Elliott MJ, Kim J, Dou A et al (2025) Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer. ESMO Open Published online. https:\/\/doi.org\/10.1016\/J.ESMOOP.2025.105286","journal-title":"ESMO Open Published online"},{"key":"7992_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-025-56658-4","author":"MJ Elliott","year":"2025","unstructured":"Elliott MJ, Echelard P, Pipinikas C et al (2025) Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay. Nat Commun Published online. https:\/\/doi.org\/10.1038\/S41467-025-56658-4","journal-title":"Nat Commun Published online"},{"key":"7992_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/S41523-023-00607-1","author":"E Zaikova","year":"2024","unstructured":"Zaikova E, Cheng BYC, Cerda V et al (2024) Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. npj Breast Cancer Published online. https:\/\/doi.org\/10.1038\/S41523-023-00607-1","journal-title":"npj Breast Cancer Published online"},{"key":"7992_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.E12553","author":"ES John","year":"2025","unstructured":"John ES, Sekhon S, Jones T et al (2025) Single arm prospective study evaluating the relationship of ctDNA molecular complete response (mCR) and pathologic complete response (pCR) in a diverse early triple-negative breast cancer patient (TNBC) population receiving neoadjuvant chemotherapy (NAC). J Clin Oncol Published online. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_SUPPL.E12553","journal-title":"J Clin Oncol Published online"},{"key":"7992_CR29","doi-asserted-by":"publisher","unstructured":"Kim H, Kim YJ, Park D et al (2021) Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: A prospective observational study. Breast Cancer Research and Treatment. Published online 2021. https:\/\/doi.org\/10.1007\/S10549-021-06296-3","DOI":"10.1007\/S10549-021-06296-3"},{"key":"7992_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/S12905-024-03486-1","author":"T Du","year":"2024","unstructured":"Du T, Yuan Y, Sun S, Gao Z, Li X (2024) Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: A multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA. BMC Women\u2019s Health. Published online. https:\/\/doi.org\/10.1186\/S12905-024-03486-1","journal-title":"Published online"},{"issue":"1","key":"7992_CR31","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/s41467-025-57988-z","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Li Y, Wei W et al (2025) Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy. Nat Commun 16(1):2786. https:\/\/doi.org\/10.1038\/s41467-025-57988-z","journal-title":"Nat Commun"},{"key":"7992_CR32","doi-asserted-by":"publisher","DOI":"10.1373\/CLINCHEM.2016.262337","author":"F Riva","year":"2017","unstructured":"Riva F, Bidard FC, Houy A et al (2017) Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem Published online. https:\/\/doi.org\/10.1373\/CLINCHEM.2016.262337","journal-title":"Clin Chem Published online"},{"key":"7992_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-024-12689-6","author":"J Chen","year":"2024","unstructured":"Chen J, Addanki S, Roy D et al (2024) Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer Published online. https:\/\/doi.org\/10.1186\/S12885-024-12689-6","journal-title":"BMC Cancer Published online"},{"key":"7992_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-022-20928-8","author":"EK Barnell","year":"2022","unstructured":"Barnell EK, Fisk B, Skidmore ZL et al (2022) Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. Sci Rep Published online. https:\/\/doi.org\/10.1038\/S41598-022-20928-8","journal-title":"Sci Rep Published online"},{"key":"7992_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/S13058-025-02026-5","author":"M Dong","year":"2025","unstructured":"Dong M, Chen J, Lu N et al (2025) Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis. Breast Cancer Res Published online. https:\/\/doi.org\/10.1186\/S13058-025-02026-5","journal-title":"Breast Cancer Res Published online"},{"key":"7992_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2025.01.021","author":"I Garc\u00eda-Murillas","year":"2025","unstructured":"Garc\u00eda-Murillas I, Abbott CW, Cutts RJ et al (2025) Whole genome sequencing powered ctDNA sequencing for breast cancer detection. Annals Oncol Published online. https:\/\/doi.org\/10.1016\/J.ANNONC.2025.01.021","journal-title":"Annals Oncol Published online"},{"key":"7992_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/S10549-024-07508-2","author":"I Garc\u00eda-Murillas","year":"2024","unstructured":"Garc\u00eda-Murillas I, Cutts RJ, Walsh-Crestani G et al (2024) Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Res Treat Published online. https:\/\/doi.org\/10.1007\/S10549-024-07508-2","journal-title":"Breast Cancer Res Treat Published online"},{"key":"7992_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-023-35362-7","author":"IM Kj\u00e6r","year":"2023","unstructured":"Kj\u00e6r IM, Kahns S, Timm S et al (2023) Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA. Sci Rep Published online. https:\/\/doi.org\/10.1038\/S41598-023-35362-7","journal-title":"Sci Rep Published online"},{"key":"7992_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/S12672-025-01940-6","author":"H Sabit","year":"2025","unstructured":"Sabit H, Attia MS, Mohamed N et al (2025) Beyond traditional biopsies: The emerging role of ctDNA and MRD on breast cancer diagnosis and treatment. Discover Oncol Published online. https:\/\/doi.org\/10.1007\/S12672-025-01940-6","journal-title":"Discover Oncol Published online"},{"key":"7992_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2024.103700","author":"R Mazzeo","year":"2024","unstructured":"Mazzeo R, Sears JE, Palmero L et al (2024) Liquid biopsy in triple-negative breast cancer: Unlocking the potential of precision oncology. ESMO Open Published online. https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.103700","journal-title":"ESMO Open Published online"},{"issue":"2","key":"7992_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner NC, Swift C, Jenkins B et al (2023) Results of the c-TRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol 34(2):200\u2013211. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.005","journal-title":"Ann Oncol"},{"key":"7992_CR42","doi-asserted-by":"publisher","unstructured":"Hunter NB, Parsons HA, Cope L et al The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease. J Clin Oncol 0, JCO\u201325-02934. https:\/\/doi.org\/10.1200\/JCO-25-02934","DOI":"10.1200\/JCO-25-02934"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07992-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:08Z","timestamp":1784017808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07992-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7992"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07992-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This work is a systematic review based exclusively on previously published studies and did not involve direct interaction with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During manuscript revision, the authors used generative artificial intelligence tools only for language polishing, editorial refinement, and improvement of text clarity. Generative AI was not used for study selection, data extraction, risk-of-bias assessment, statistical analysis, evidence interpretation, or the generation of scientific conclusions. All authors critically reviewed, edited, and approved the final manuscript and take full responsibility for its content.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative artificial intelligence"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}